Antifungal Agents

• 

  Subject Areas on Research

  • "Is there an emerging need for new antifungals?". 
  • 4-oxatetradecanoic acid is fungicidal for Cryptococcus neoformans and inhibits replication of human immunodeficiency virus I. 
  • 5-fluorocytosine resistance is associated with hypermutation and alterations in capsule biosynthesis in Cryptococcus. 
  • 74-Year-Old Woman With Fatigue, Anorexia, and Abdominal Pain. 
  • A 37-Year-Old Man With Pleuritic Chest Pain. 
  • A Novel Resistance Pathway for Calcineurin Inhibitors in the Human-Pathogenic Mucorales Mucor circinelloides. 
  • A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis. 
  • A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis. 
  • A flucytosine-responsive Mbp1/Swi4-like protein, Mbs1, plays pleiotropic roles in antifungal drug resistance, stress response, and virulence of Cryptococcus neoformans. 
  • A meta-analysis of medical versus surgical therapy for Candida endocarditis. 
  • A non-canonical RNAi pathway controls virulence and genome stability in Mucorales. 
  • A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. 
  • A tetraploid intermediate precedes aneuploid formation in yeasts exposed to fluconazole. 
  • AIDS-associated Penicillium marneffei infection of the central nervous system. 
  • AIDS‐associated Cryptococcus neoformans and Penicillium marneffei coinfection: a therapeutic dilemma in resource‐limited settings. 
  • AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. 
  • Activation of the sphingomyelin cycle by brefeldin A: effects of brefeldin A on differentiation and implications for a role for ceramide in regulation of protein trafficking. 
  • Adoptive transfer and specific active immunization of patients with malignant melanoma. 
  • Advances in the treatment of invasive neonatal candidiasis. 
  • Adverse drug reactions to systemic antifungals. Prevention and management. 
  • Aerosol and other novel administrations for prevention and treatment of invasive aspergillosis. 
  • Aerosolized antifungal prophylaxis: the winds of change? 
  • Agents for treatment of invasive fungal infections. 
  • Amebic keratitis in a wearer of disposable contact lenses due to a mixed Vahlkampfia and Hartmannella infection. 
  • Amphotericin B alters the affinity and functional activity of the oligopeptide chemotactic factor receptor on human polymorphonuclear leukocytes. 
  • Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. 
  • An Antifungal Combination Matrix Identifies a Rich Pool of Adjuvant Molecules that Enhance Drug Activity against Diverse Fungal Pathogens. 
  • An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. 
  • An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. 
  • An unwelcome guest: Aspergillus colonization in lung transplantation and its association with bronchiolitis obliterans syndrome. 
  • Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. 
  • Anidulafungin: a new echinocandin for the treatment of fungal infections. 
  • Anti-cryptococcal activity of preussolides A and B, phosphoethanolamine-substituted 24-membered macrolides, and leptosin C from coprophilous isolates of Preussia typharum. 
  • Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species. 
  • Antifungal Drugs in Newborns and Children. 
  • Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis. 
  • Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. 
  • Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. 
  • Antifungal activity of compounds targeting the Hsp90-calcineurin pathway against various mould species. 
  • Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective. 
  • Antifungal attributes of immunosuppressive agents: new paradigms in management and elucidating the pathophysiologic basis of opportunistic mycoses in organ transplant recipients. 
  • Antifungal catheter lock therapy for the management of a persistent Candida albicans bloodstream infection in an adult receiving hemodialysis. 
  • Antifungal effects of cyclosporine and FK 506 are mediated via immunophilin-dependent calcineurin inhibition. 
  • Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection. 
  • Antifungal pharmacodynamics: review of the literature and clinical applications. 
  • Antifungal pharmacotherapy for invasive mould infections. 
  • Antifungal prophylaxis in adult hematopoietic stem cell transplant recipients. 
  • Antifungal prophylaxis: to prevent or not. 
  • Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches. 
  • Antifungal resistance: the clinical front. 
  • Antifungal serum concentration monitoring: an update. 
  • Antifungal susceptibilities of Cryptococcus neoformans. 
  • Antifungal therapy and its use in surgical treatment. 
  • Antifungal therapy and outcomes in infants with invasive Candida infections. 
  • Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update. 
  • Antifungal treatment in pediatric patients. 
  • Antifungals in Clinical Use and the Pipeline. 
  • Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. 
  • Antisense repression in Cryptococcus neoformans as a laboratory tool and potential antifungal strategy. 
  • Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis. 
  • Aryl-alkyl-lysines: Membrane-Active Fungicides That Act against Biofilms of Candida albicans. 
  • Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole. 
  • Aspergillus nidulans causing primary cutaneous aspergillosis in an immunocompetent patient. 
  • Aspergillus niger: an unusual cause of invasive pulmonary aspergillosis. 
  • Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. 
  • Azole antifungals: 35 years of invasive fungal infection management. 
  • Black Molds and Melanized Yeasts Pathogenic to Humans. 
  • Blastomycosis. 
  • Blastomycosis: a case study of a dimorphic fungal disease. 
  • Breakthrough invasive candidiasis in patients on micafungin. 
  • Breakthrough invasive fungal infections: Who is at risk? 
  • Broad antifungal resistance mediated by RNAi-dependent epimutation in the basal human fungal pathogen Mucor circinelloides. 
  • Broad spectrum antibacterial and antifungal polymeric paint materials: synthesis, structure-activity relationship, and membrane-active mode of action. 
  • Broad spectrum triazoles for invasive mould infections in adults: Which drug and when? 
  • Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis. 
  • Calcineurin controls hyphal growth, virulence, and drug tolerance of Candida tropicalis. 
  • Calcineurin governs thermotolerance and virulence of Cryptococcus gattii. 
  • Calcineurin in fungal virulence and drug resistance: Prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach. 
  • Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. 
  • Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. 
  • Calcineurin is essential for survival during membrane stress in Candida albicans. 
  • Calcineurin is required for pseudohyphal growth, virulence, and drug resistance in Candida lusitaniae. 
  • Calcineurin is required for virulence of Cryptococcus neoformans. 
  • Calcineurin orchestrates dimorphic transitions, antifungal drug responses and host-pathogen interactions of the pathogenic mucoralean fungus Mucor circinelloides. 
  • Calcineurin promotes infection of the cornea by Candida albicans and can be targeted to enhance fluconazole therapy. 
  • Calcineurin, Mpk1 and Hog1 MAPK pathways independently control fludioxonil antifungal sensitivity in Cryptococcus neoformans. 
  • Calcium-Mediated Induction of Paradoxical Growth following Caspofungin Treatment Is Associated with Calcineurin Activation and Phosphorylation in Aspergillus fumigatus. 
  • Calcofluor white combination antifungal treatments for Trichophyton rubrum and Candida albicans. 
  • Campafungins: Inhibitors of Candida albicans and Cryptococcus neoformans Hyphal Growth. 
  • Candida albicans reprioritizes metal handling during fluconazole stress. 
  • Candida auris. 
  • Candida glabrata endophthalmitis following penetrating keratoplasty. 
  • Candida infective endocarditis. 
  • Candida infective endocarditis: an observational cohort study with a focus on therapy. 
  • Candida pneumonia in a term infant after prolonged use of inhaled corticosteroids for bronchopulmonary dysplasia (BPD). 
  • Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents. 
  • Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation. 
  • Case 215: voriconazole-induced periostitis. 
  • Case 4: Weakness and Headaches in a 14-year-old Boy. 
  • Caspofungin exposure alters the core septin AspB interactome of Aspergillus fumigatus. 
  • Caspofungin for invasive candidiasis at a tertiary care medical center. 
  • Caspofungin for the treatment of azole resistant candidemia in a premature infant. 
  • Caspofungin versus amphotericin B for invasive candidiasis. 
  • Caspofungin: first approved agent in a new class of antifungals. 
  • Cationic amphiphilic Zn-porphyrin with high antifungal photodynamic potency. 
  • Cell biology. A fungal Achilles' heel. 
  • Cell wall integrity is dependent on the PKC1 signal transduction pathway in Cryptococcus neoformans. 
  • Central Role of the Trehalose Biosynthesis Pathway in the Pathogenesis of Human Fungal Infections: Opportunities and Challenges for Therapeutic Development. 
  • Cerebral phaeohyphomycosis in an immunodeficient child treated medically with combination antifungal therapy. 
  • Cerebral phaeohyphomycosis mimics high-grade astrocytoma. 
  • Changes in the incidence of candidiasis in neonatal intensive care units. 
  • Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis. 
  • Characterization of Isavuconazole serum concentrations after enteral feeding tube administration in a hospitalized cohort: A case series. 
  • Chemical and functional properties of metal chelators that mobilize copper to elicit fungal killing of Cryptococcus neoformans. 
  • Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature. 
  • Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. 
  • Clinical Characteristics, Diagnosis, Management, and Outcomes of Disseminated Emmonsiosis: A Retrospective Case Series. 
  • Clinical and microbial spectrum of fungal keratitis in Singapore: a 5-year retrospective study. 
  • Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. 
  • Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope® registry. 
  • Clinical characteristics and response to prophylactic fluconazole of preterm VLBW neonates with baseline and acquired fungal colonisation in NICU: data from a multicentre RCT. 
  • Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. 
  • Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. 
  • Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. 
  • Clonal and spontaneous origins of fluconazole resistance in Candida albicans. 
  • Colony size can be used to determine the MIC of fluconazole for pathogenic yeasts. 
  • Combination antifungal therapy. 
  • Combination antifungal therapy: what can and should we expect? 
  • Comment on: "Efficacies and merits of the cotton swab technique for diagnosing tinea capitis in the pediatric population". 
  • Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future. 
  • Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. 
  • Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. 
  • Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets. 
  • Comparative transcriptome analysis reveals novel roles of the Ras and cyclic AMP signaling pathways in environmental stress response and antifungal drug sensitivity in Cryptococcus neoformans. 
  • Comparing Etest and Broth Microdilution for Antifungal Susceptibility Testing of the Most-Relevant Pathogenic Molds. 
  • Comparison of Cryptococcus gattii/neoformans Species Complex to Related Genera (Papiliotrema and Naganishia) Reveal Variances in Virulence Associated Factors and Antifungal Susceptibility. 
  • Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis. 
  • Comparison of caspofungin and amphotericin B for invasive candidiasis. 
  • Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults. 
  • Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. 
  • Congenital candidiasis: an uncommon skin eruption presenting at birth. 
  • Congenital cutaneous candidiasis: a case presentation. 
  • Conserved Mechanism of 2'-Phosphorylation-Aided Amide Ligation in Peptidyl Nucleoside Biosynthesis. 
  • Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. 
  • Copper Availability Influences the Transcriptomic Response of Candida albicans to Fluconazole Stress. 
  • Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. 
  • Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. 
  • Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options. 
  • Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures. 
  • Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers? 
  • Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. 
  • Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. 
  • Could risk assessment for non-albicans Candida improve empiric treatment for invasive candidiasis? 
  • Cryptic Phosphorylation-Mediated Divergent Biosynthesis of High-Carbon Sugar Nucleoside Antifungals. 
  • Cryptic phosphorylation in nucleoside natural product biosynthesis. 
  • Cryptococcal meningitis in patients with glioma: a report of two cases. 
  • Cryptococcal meningoencephalitis: time for action. 
  • Cryptococcal osteomyelitis in an adolescent survivor of T-cell acute lymphoblastic leukemia. 
  • Cryptococcosis Serotypes Impact Outcome and Provide Evidence of Cryptococcus neoformans Speciation. 
  • Cryptococcosis after solid organ transplantation. 
  • Cryptococcosis diagnosis and treatment: What do we know now. 
  • Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. 
  • Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. 
  • Cryptococcosis. 
  • Cryptococcosis. 
  • Cryptococcus gattii genotype VGI infection in New England. 
  • Cryptococcus neoformans methionine synthase: expression analysis and requirement for virulence. 
  • Cryptococcus neoformans phosphoinositide-dependent kinase 1 (PDK1) ortholog is required for stress tolerance and survival in murine phagocytes. 
  • Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. 
  • Crystal structures of the fungal pathogen Aspergillus fumigatus protein farnesyltransferase complexed with substrates and inhibitors reveal features for antifungal drug design. 
  • Current options in antifungal pharmacotherapy. 
  • Current situation of endemic mycosis in the Americas and the Caribbean: Proceedings of the first international meeting on endemic mycoses of the Americas (IMEMA). 
  • Cutaneous cryptococcosis in solid organ transplant recipients. 
  • Cutaneous hyalohyphomycosis caused by Acremonium in an immunocompetent patient. 
  • Cytocidal amino acid starvation of Saccharomyces cerevisiae and Candida albicans acetolactate synthase (ilv2{Delta}) mutants is influenced by the carbon source and rapamycin. 
  • Defining COVID-19-associated pulmonary aspergillosis: systematic review and meta-analysis. 
  • Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. 
  • Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. 
  • Delayed Diagnosis of Disseminated Cryptococcosis with Associated Meningoencephalitis in an Immunocompetent Septuagenarian Host. 
  • Deletion of Cryptococcus neoformans AIF ortholog promotes chromosome aneuploidy and fluconazole-resistance in a metacaspase-independent manner. 
  • Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity. 
  • Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients. 
  • Development and evaluation of a real-time polymerase chain reaction assay for the rapid detection of Talaromyces marneffei MP1 gene in human plasma. 
  • Diagnosis and Management of Systemic Endemic Mycoses Causing Pulmonary Disease. 
  • Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. 
  • Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. 
  • Diguanidino and "reversed" diamidino 2,5-diarylfurans as antimicrobial agents. 
  • Dihydropteroate synthase mutations in Pneumocystis pneumonia: impact of applying different definitions of prophylaxis, mortality endpoints and mutant in a single cohort. 
  • Discovery of Ibomycin, a Potent Antifungal Weapon. 
  • Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae. 
  • Do not abandon amphotericin B as an antifungal bladder irrigant. 
  • Drug-Resistant Epimutants Exhibit Organ-Specific Stability and Induction during Murine Infections Caused by the Human Fungal Pathogen Mucor circinelloides. 
  • Dual action antifungal small molecule modulates multidrug efflux and TOR signaling. 
  • Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. 
  • Dynamic and heterogeneous mutations to fluconazole resistance in Cryptococcus neoformans. 
  • Dynamic duo takes down fungal villains. 
  • ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. 
  • Early treatment of candidemia in adults: a review. 
  • Echinocandin pharmacodynamics: review and clinical implications. 
  • Echinocandins for the nursery: an update. 
  • Echinocandins: a wealth of choice--how clinically different are they? 
  • Echinocandins: addressing outstanding questions surrounding treatment of invasive fungal infections. 
  • Echinocandins: role in antifungal therapy, 2005. 
  • Editorial commentary: Fluconazole therapeutic drug monitoring in children with cancer: not today. 
  • Effect of fluconazole prophylaxis on Candida fluconazole susceptibility in premature infants. 
  • Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial. 
  • Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells. 
  • Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis. 
  • Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days. 
  • Efficiently killing a sugar-coated yeast. 
  • Elucidating the Candida albicans calcineurin signaling cascade controlling stress response and virulence. 
  • Emergence of the Molds Other than Aspergillus in Immunocompromised Patients. 
  • Emerging Issues in Antifungal Resistance. 
  • Emerging echinocandins for treatment of invasive fungal infections. 
  • Emergomyces canadensis, a Dimorphic Fungus Causing Fatal Systemic Human Disease in North America. 
  • Emmonsia helica Infection in HIV-Infected Man, California, USA. 
  • Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis. 
  • Empirical therapy for neonatal candidemia in very low birth weight infants. 
  • Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET). 
  • Endolysosomal membrane trafficking complexes drive nutrient-dependent TORC1 signaling to control cell growth in Saccharomyces cerevisiae. 
  • Engineering of New Pneumocandin Side-Chain Analogues from Glarea lozoyensis by Mutasynthesis and Evaluation of Their Antifungal Activity. 
  • Epigenetic mechanisms of drug resistance in fungi. 
  • Erg6 affects membrane composition and virulence of the human fungal pathogen Cryptococcus neoformans. 
  • Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. 
  • Establishment and Use of Epidemiological Cutoff Values for Molds and Yeasts by Use of the Clinical and Laboratory Standards Institute M57 Standard. 
  • Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. 
  • Evaluation and management of fungal infections in immunocompromised patients. 
  • Evaluation of in vitro antifungal activity of LY121019. 
  • Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. 
  • Exploiting innate immune cell activation of a copper-dependent antimicrobial agent during infection. 
  • Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials. 
  • External Evaluation of Two Fluconazole Infant Population Pharmacokinetic Models. 
  • FKBP12-Dependent Inhibition of Calcineurin Mediates Immunosuppressive Antifungal Drug Action in Malassezia. 
  • Factors associated with mortality in transplant patients with invasive aspergillosis. 
  • Failure of amphotericin B colloidal dispersion in the treatment of paracoccidioidomycosis. 
  • Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patients. 
  • Fatty acid synthesis is essential for survival of Cryptococcus neoformans and a potential fungicidal target. 
  • First, do no harm. 
  • Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. 
  • Fluconazole Prophylaxis for the Prevention of Candidiasis in Premature Infants: A Meta-analysis Using Patient-level Data. 
  • Fluconazole analogues with metal-binding motifs impact metal-dependent processes and demonstrate antifungal activity in Candida albicans. 
  • Fluconazole loading dose pharmacokinetics and safety in infants. 
  • Fluconazole pharmacokinetics and safety in premature infants. 
  • Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation. 
  • Fluconazole prophylaxis for prevention of invasive candidiasis in infants. 
  • Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450. 
  • Four genomic clades of Candida auris identified in Canada, 2012-2019. 
  • Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds. 
  • Fungal diagnosis: how do we do it and can we do better? 
  • Fungal infection of a ventriculoperitoneal shunt: histoplasmosis diagnosis and treatment. 
  • Fungal infections in HIV/AIDS. 
  • Fungal pathogens. 
  • Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. 
  • Fungal phospholipase activity and susceptibility to lipid preparations of amphotericin B. 
  • Fungal scleritis after cataract surgery. Successful outcome using itraconazole. 
  • Fungal virulence genes as targets for antifungal chemotherapy. 
  • Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. 
  • Genome variation in Cryptococcus gattii, an emerging pathogen of immunocompetent hosts. 
  • Genomic characterization of recurrent mold infections in thoracic transplant recipients. 
  • Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. 
  • Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. 
  • Griseofulvin impairs intraerythrocytic growth of Plasmodium falciparum through ferrochelatase inhibition but lacks activity in an experimental human infection study. 
  • Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. 
  • Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. 
  • Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents. 
  • Heterothallic mating in Mucor irregularis and first isolate of the species outside of Asia. 
  • High Rates of Influenza-Associated Invasive Pulmonary Aspergillosis May Not Be Universal: A Retrospective Cohort Study from Alberta, Canada. 
  • Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding. 
  • Hsp70 and the Cochaperone StiA (Hop) Orchestrate Hsp90-Mediated Caspofungin Tolerance in Aspergillus fumigatus. 
  • Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. 
  • Identification of a key lysine residue in heat shock protein 90 required for azole and echinocandin resistance in Aspergillus fumigatus. 
  • Identification of cyclosporin C from Amphichorda felina using a Cryptococcus neoformans differential temperature sensitivity assay. 
  • Impact of automatic infectious diseases consultation on the management of fungemia at a large academic medical center. 
  • Importance of the beta12-beta13 loop in protein phosphatase-1 catalytic subunit for inhibition by toxins and mammalian protein inhibitors. 
  • Improved outcome in central nervous system aspergillosis, using voriconazole treatment. 
  • In Vitro Antifungal Susceptibility of Yeast and Mold Phases of Isolates of Dimorphic Fungal Pathogen Emergomyces africanus (Formerly Emmonsia sp.) from HIV-Infected South African Patients. 
  • In Vitro and In Vivo Assessment of FK506 Analogs as Novel Antifungal Drug Candidates. 
  • In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus. 
  • In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. 
  • In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. 
  • In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. 
  • In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans. 
  • In vitro antifungal activities of a series of dication-substituted carbazoles, furans, and benzimidazoles. 
  • In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. 
  • In vitro characterization of nebulizer delivery of liposomal amphotericin B aerosols. 
  • In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. 
  • In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. 
  • In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. 
  • In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats. 
  • In-vitro activity of dicationic aromatic compounds and fluconazole against Cryptococcus neoformans and Candida spp. 
  • Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. 
  • Infection prophylaxis in pancreas transplant recipients. 
  • Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. 
  • Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. 
  • Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers. 
  • Initial characterization of micafungin pulmonary delivery via two different nebulizers and multivariate data analysis of aerosol mass distribution profiles. 
  • Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. 
  • Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. 
  • Introduction. Issues concerning antifungal susceptibility testing. 
  • Invasive Candida infections in the neonate. 
  • Invasive Curvularia Infection in Pediatric Patients With Hematologic Malignancy Identified by Fungal Sequencing. 
  • Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis. 
  • Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. 
  • Invasive fungal infections in neonates: a review. 
  • Invasive mould infections: a multi-disciplinary update. 
  • Invasive mycoses: evolving challenges and opportunities in antifungal therapy (multimedia activity). 
  • Invasive mycoses: evolving challenges and opportunities in antifungal therapy. Introduction. 
  • Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. 
  • Is it time to abandon the use of amphotericin B bladder irrigation? 
  • Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. 
  • Isavuconazole for treatment of rare invasive fungal diseases. 
  • Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. 
  • Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. 
  • Isolated thrombocytopenia associated with oral terbinafine. 
  • Isolation and characterization of viridin, a new 65 kDa antifungal protein from the mould Trichoderma viride. 
  • Itraconazole and antiretroviral therapy: strategies for empirical dosing - Author's reply. 
  • Itraconazole and antiretroviral therapy: strategies for empirical dosing. 
  • Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. 
  • Itraconazole or Amphotericin B for Talaromycosis. 
  • Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. The ARDS Network. 
  • Kin1 kinase localizes at the hyphal septum and is dephosphorylated by calcineurin but is dispensable for septation and virulence in the human pathogen Aspergillus fumigatus. 
  • Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. 
  • Letter: Polyene antibiotics. VI. The structures of dermostatins A and B. 
  • Leveraging Fungal and Human Calcineurin-Inhibitor Structures, Biophysical Data, and Dynamics To Design Selective and Nonimmunosuppressive FK506 Analogs. 
  • Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population. 
  • Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia. 
  • Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients. 
  • Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. 
  • Liposomal amphotericin B: clinical experience and perspectives. 
  • Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals. 
  • Lyme Disease Serology. 
  • MTL genotypes, phenotypic switching, and susceptibility profiles of Candida parapsilosis species group compared to Lodderomyces elongisporus. 
  • Mammalian RAFT1 kinase domain provides rapamycin-sensitive TOR function in yeast. 
  • Management and Outcomes of Acute Respiratory Distress Syndrome Caused by Blastomycosis: A Retrospective Case Series. 
  • Management of an Outbreak of Exophiala dermatitidis Bloodstream Infections at an Outpatient Oncology Clinic. 
  • Management of cryptococcosis: how are we doing? 
  • Management of drug and food interactions with azole antifungal agents in transplant recipients. 
  • Management of invasive mycoses in hematology patients: current approaches. 
  • Metal Chelation as a Powerful Strategy to Probe Cellular Circuitry Governing Fungal Drug Resistance and Morphogenesis. 
  • Micafungin: the US perspective. 
  • Mitochondrial Genome Variation Affects Multiple Respiration and Nonrespiration Phenotypes in Saccharomyces cerevisiae. 
  • Molecular approaches to identify novel targets for future development of antifungal agents. 
  • Molecular cloning and characterization of Aspergillus nidulans cyclophilin B. 
  • Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. 
  • Molecular umbrella-amphotericin B conjugates. 
  • Mortality rates in comparative trials of formulations of amphotericin B. 
  • Mucormycosis Rhinosinusitis at Diagnosis of Acute Lymphoblastic Leukemia: Diagnostics and Management Challenges in a Low-Middle-income Country. 
  • Mucormycosis. 
  • N-myristoylation of Arf proteins in Candida albicans: an in vivo assay for evaluating antifungal inhibitors of myristoyl-CoA: protein N-myristoyltransferase. 
  • Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment. 
  • Natural product ligands of FKBP12: Immunosuppressive antifungal agents FK506, rapamycin, and beyond. 
  • Nebulizer delivery of micafungin aerosols. 
  • Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScopeⓇ-Global Registry for Emerging Fungal Infections. 
  • Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. 
  • Neonatal candidiasis. 
  • Neonatal candidiasis: prophylaxis and treatment. 
  • Neonatal fungal infections: when to treat? 
  • Neonatal invasive candidiasis: updates on clinical management and prevention. 
  • Network-assisted genetic dissection of pathogenicity and drug resistance in the opportunistic human pathogenic fungus Cryptococcus neoformans. 
  • New Spins on Old Drugs: Enhancing Activity of Antifungals. 
  • New antifungal agents under development in children and neonates. 
  • New antifungal agents. 
  • New antifungal agents. 
  • New facets of antifungal therapy. 
  • New fungal metabolite geranylgeranyltransferase inhibitors with antifungal activity. 
  • Newer antifungal therapy for emerging fungal pathogens. 
  • Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. 
  • Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi. 
  • Novel biologically active nonpeptidic inhibitors of myristoylCoA:protein N-myristoyltransferase. 
  • Novel modes of antifungal drug administration. 
  • Nuances of new anti-Aspergillus antifungals. 
  • Nutrient signaling through TOR kinases controls gene expression and cellular differentiation in fungi. 
  • Old and new: appropriate dosing for neonatal antifungal drugs in the nursery. 
  • On Fruits and Fungi: A Risk of Antifungal Usage in Food Storage and Distribution in Driving Drug Resistance in Candida auris. 
  • Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. 
  • Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group. 
  • Orbitofascial conidiobolomycosis in a child. 
  • Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. 
  • Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. 
  • Outcomes of cryptococcosis in renal transplant recipients in a less-resourced health care system. 
  • Overview of treatment options for invasive fungal infections. 
  • PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. 
  • Paecilomyces lilacinus septic olecranon bursitis in an immunocompetent host. 
  • Paradoxical worsening of Emergomyces africanus infection in an HIV-infected male on itraconazole and antiretroviral therapy. 
  • Pediatric Antibacterial and Antifungal Trials From 2007 to 2017. 
  • Pediatric antifungal agents. 
  • Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. 
  • Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. 
  • Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET). 
  • Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis. 
  • Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. 
  • Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions. 
  • Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. 
  • Pharmacokinetic, efficacy, and safety considerations for the use of antifungal drugs in the neonatal population. 
  • Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation. 
  • Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications. 
  • Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints. 
  • Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation. 
  • Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. 
  • Pharmacokinetics of an elevated dosage of micafungin in premature neonates. 
  • Pharmacokinetics of antifungal agents in children. 
  • Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. 
  • Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. 
  • Pharmacological resolution of a multiloculated Candida spp. liver abscess in a preterm neonate. 
  • Pharmacotherapy of disseminated histoplasmosis in patients with AIDS. 
  • Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. 
  • Phenotypic and genotypic evaluation of fluconazole resistance in vaginal Candida strains isolated from HIV-infected women from Brazil. 
  • Phosphate is the third nutrient monitored by TOR in Candida albicans and provides a target for fungal-specific indirect TOR inhibition. 
  • Phosphorylation of Calcineurin at a novel serine-proline rich region orchestrates hyphal growth and virulence in Aspergillus fumigatus. 
  • Physiologically Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life Support: Fluconazole in Children on ECMO. 
  • Physiologically-Based Pharmacokinetic Modeling of Fluconazole Using Plasma and Cerebrospinal Fluid Samples From Preterm and Term Infants. 
  • Polyene antibiotics. IV. Structure of chainin. 
  • Population Analysis of Anidulafungin in Infants to Older Adults With Confirmed or Suspected Invasive Candidiasis. 
  • Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei. 
  • Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei. 
  • Population Pharmacokinetics of Fluconazole in Premature Infants with Birth Weights Less than 750 Grams. 
  • Population pharmacokinetics of fluconazole in young infants. 
  • Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents. 
  • Population pharmacokinetics of micafungin in neonates and young infants. 
  • Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. 
  • Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment. 
  • Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans. 
  • Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. 
  • Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update. 
  • Posaconazole. 
  • Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections. 
  • Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. 
  • Predictors and outcomes of Candida bloodstream infection: eight-year surveillance, western Saudi Arabia. 
  • Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. 
  • Preventing Pulmonary Aspergillosis: Can We Breathe Easy? 
  • Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. 
  • Prognosis and treatment effects of HIV-associated talaromycosis in a real-world patient cohort. 
  • Prophylaxis of invasive mycoses in solid organ transplantation. 
  • Protein kinase activity and identification of a toxic effector domain of the target of rapamycin TOR proteins in yeast. 
  • Pulmonary blastomycosis presenting as primary lung cancer. 
  • Purification of alpha-sarcin and an antifungal protein from Aspergillus giganteus by blue sepharose CL-6B affinity chromatography. 
  • Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds. 
  • Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole. 
  • Quality control guidelines for amphotericin B, Itraconazole, posaconazole, and voriconazole disk diffusion susceptibility tests with nonsupplemented Mueller-Hinton Agar (CLSI M51-A document) for nondermatophyte Filamentous Fungi. 
  • RNAi-Based Functional Genomics Identifies New Virulence Determinants in Mucormycosis. 
  • Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. 
  • Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR. 
  • Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans. 
  • Rapamycin exerts antifungal activity in vitro and in vivo against Mucor circinelloides via FKBP12-dependent inhibition of Tor. 
  • Rapamycin induces the G0 program of transcriptional repression in yeast by interfering with the TOR signaling pathway. 
  • Rare and emerging fungal pulmonary infections. 
  • Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy. 
  • Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. 
  • Real-world effectiveness of antifungal prophylaxis with posaconazole as the primary agent in patients with haematological malignancies. 
  • Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone. 
  • Recent advances in antifungal pharmacotherapy for invasive fungal infections. 
  • Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia. 
  • Recent advances in the treatment of life-threatening, invasive fungal infections. 
  • Recovery from disseminated candidiasis in a premature neonate. 
  • Reduced Visual Acuity Following Kidney Stone Extraction. 
  • Repeated therapeutic lumbar punctures in cryptococcal meningitis - necessity and/or opportunity? 
  • Reply to Argüelles. 
  • Reply to Marinelli and Rotstein. 
  • Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. 
  • Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. 
  • Risk factors and mortality in invasive Rasamsonia spp. infection: Analysis of cases in the FungiScope® registry and from the literature. 
  • Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. 
  • Role of Antifungal Susceptibility Testing in Non-Aspergillus Invasive Mold Infections. 
  • Role of Arf-like proteins (Arl1 and Arl2) of Mucor circinelloides in virulence and antifungal susceptibility. 
  • Role of echinocandins in the management of fungal infections in neonates. 
  • Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. 
  • Role of the Non-Canonical RNAi Pathway in the Antifungal Resistance and Virulence of Mucorales. 
  • Roles for Stress Response and Cell Wall Biosynthesis Pathways in Caspofungin Tolerance in Cryptococcus neoformans. 
  • Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. 
  • Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. 
  • Safety of Inhaled Amphotericin B Lipid Complex as Antifungal Prophylaxis in Lung Transplant Recipients. 
  • Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. 
  • Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. 
  • Safety of micafungin in infants: insights into optimal dosing. 
  • Safety, Effectiveness and Exposure-response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records. 
  • Scanning Quadrupole Data-Independent Acquisition, Part B: Application to the Analysis of the Calcineurin-Interacting Proteins during Treatment of Aspergillus fumigatus with Azole and Echinocandin Antifungal Drugs. 
  • Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. 
  • Scedosporium species infections and treatments. 
  • Severe cholestasis related to intraconazole for the treatment of onychomycosis. 
  • Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. 
  • Signaling cascades as drug targets in model and pathogenic fungi. 
  • Simple Strategy for Taming Membrane-Disrupting Antibiotics. 
  • Small intestinal histoplasmosis: successful treatment with itraconazole in an immunocompetent host. 
  • Sodium bicarbonate gels: a new promising strategy for the treatment of vulvovaginal candidosis. 
  • Specific Histidine Residues Confer Histatin Peptides with Copper-Dependent Activity against Candida albicans 
  • Sphaerostilbellins, New Antimicrobial Aminolipopeptide Peptaibiotics from Sphaerostilbella toxica. 
  • Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy. 
  • StableIsotope Labeling with Amino Acids in Cell Culture (SILAC)-based strategy for proteome-wide thermodynamic analysis of protein-ligand binding interactions. 
  • Stereochemical aspects of itraconazole metabolism in vitro and in vivo. 
  • Sterol-Response Pathways Mediate Alkaline Survival in Diverse Fungi. 
  • Strategies to manage antifungal drug resistance. 
  • Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis. 
  • Structural and In Vivo Studies on Trehalose-6-Phosphate Synthase from Pathogenic Fungi Provide Insights into Its Catalytic Mechanism, Biological Necessity, and Potential for Novel Antifungal Drug Design. 
  • Structural basis for inhibition and regulation of a chitin synthase from Candida albicans. 
  • Structure-Guided Discovery of Potent Antifungals that Prevent Ras Signaling by Inhibiting Protein Farnesyltransferase. 
  • Structure-Guided Synthesis of FK506 and FK520 Analogs with Increased Selectivity Exhibit In Vivo Therapeutic Efficacy against Cryptococcus. 
  • Structure-in vitro activity relationships of pentamidine analogues and dication-substituted bis-benzimidazoles as new antifungal agents. 
  • Structures of Cryptococcus neoformans protein farnesyltransferase reveal strategies for developing inhibitors that target fungal pathogens. 
  • Study of renal safety in amphotericin B lipid complex-treated patients. 
  • Successful management of a simultaneous Aspergillus fumigatus and Absidia corymbifera invasive fungal infection. 
  • Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. 
  • Successful treatment of Ochroconis gallopavum infection in an immunocompetent host. 
  • Successful treatment of Trichosporon mucoides infection with fluconazole in a heart and kidney transplant recipient. 
  • Successful treatment of cryptococcal ventriculoatrial shunt infection with systemic therapy alone. 
  • Successful treatment of disseminated cryptococcal infection in a pediatric acute lymphoblastic leukemia patient during induction. 
  • Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. 
  • Successfully treated postoperative Candida parakrusei endophthalmitis. 
  • Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. 
  • Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. 
  • Synthesis and antifungal activities of miltefosine analogs. 
  • System for expression of microsporidian methionine amino peptidase type 2 (MetAP2) in the yeast Saccharomyces cerevisiae. 
  • TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. 
  • Taming Amphotericin B. 
  • Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model. 
  • Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. 
  • The Cryptococcus neoformans Flc1 Homologue Controls Calcium Homeostasis and Confers Fungal Pathogenicity in the Infected Hosts. 
  • The Cryptococcus neoformans MAP kinase Mpk1 regulates cell integrity in response to antifungal drugs and loss of calcineurin function. 
  • The Cryptococcus neoformans genome sequencing project. 
  • The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. 
  • The Hsp90 co-chaperone Sgt1 governs Candida albicans morphogenesis and drug resistance. 
  • The Role of Adjunctive Therapies in the Management of Invasive Sino-Orbital Infection. 
  • The TOR kinases link nutrient sensing to cell growth. 
  • The antifungal pipeline: a reality check. 
  • The authors respond to "Candida auris can be identified accurately". 
  • The calcineurin target, Crz1, functions in azole tolerance but is not required for virulence of Candida albicans. 
  • The current state of Clinical Mycology in Eastern and South-Eastern Europe. 
  • The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis). 
  • The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). 
  • The epidemiology and diagnosis of invasive candidiasis among premature infants. 
  • The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). 
  • The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. 
  • The impact of the host on fungal infections. 
  • The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. 
  • The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine. 
  • The role of the de novo pyrimidine biosynthetic pathway in Cryptococcus neoformans high temperature growth and virulence. 
  • The structures of dermostatins A and B 1,2. 
  • The tor pathway regulates gene expression by linking nutrient sensing to histone acetylation. 
  • The use of antifungal therapy in neonatal intensive care. 
  • The war on cryptococcosis: A Review of the antifungal arsenal. 
  • Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children. 
  • Three phylogenetic groups have driven the recent population expansion of Cryptococcus neoformans. 
  • Tolerability profile of the current antifungal armoury. 
  • Transcriptional regulation of chitin synthases by calcineurin controls paradoxical growth of Aspergillus fumigatus in response to caspofungin. 
  • Transposon mobilization in the human fungal pathogen Cryptococcus is mutagenic during infection and promotes drug resistance in vitro. 
  • Treatment and prophylaxis of invasive candidiasis. 
  • Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304. 
  • Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. 
  • Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. 
  • Treatment of neonatal fungal infections. 
  • Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. 
  • Treatment of sporotrichosis with itraconazole. NIAID Mycoses Study Group. 
  • Treatment options for invasive fungal infections. 
  • Trehalose pathway as an antifungal target. 
  • Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole. 
  • Uncontrolled transposition following RNAi loss causes hypermutation and antifungal drug resistance in clinical isolates of Cryptococcus neoformans. 
  • Unisexual and heterosexual meiotic reproduction generate aneuploidy and phenotypic diversity de novo in the yeast Cryptococcus neoformans. 
  • Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients. 
  • Uptake of itraconazole by alveolar macrophages. 
  • Use of Multimodality Imaging in Diagnosing Invasive Fungal Diseases of the Heart. 
  • Use of external ventriculostomy and intrathecal anti-fungal treatment in cerebral mucormycotic abscess. 
  • Use of fluconazole in a patient with documented malabsorption of ketoconazole. 
  • Use of newer antifungal therapies in clinical practice: what do the data tell us? 
  • Variability of Hydroxy-Itraconazole in Relation to Itraconazole Bloodstream Concentrations. 
  • Vav Proteins Are Key Regulators of Card9 Signaling for Innate Antifungal Immunity. 
  • Voriconazole Treatment for an Infant With Intractable Candida glabrata Meningitis. 
  • Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. 
  • Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. 
  • Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial. 
  • Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008-2019. 
  • Voriconazole treatment for less-common, emerging, or refractory fungal infections. 
  • When primary antifungal therapy fails. 
  • When to suspect fungal infection in neonates: A clinical comparison of Candida albicans and Candida parapsilosis fungemia with coagulase-negative staphylococcal bacteremia. 
  • Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. 
  • Zinc Binding Inhibits Cellular Uptake and Antifungal Activity of Histatin-5 in Candida albicans . 
  • Zygomycosis: the re-emerging fungal infection. 
  • β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. 
• 

  Keywords of People

  • Bobay, Benjamin, Research Associate, Senior, Radiology
  • Cohen-Wolkowiez, Michael, Kiser-Arena Distinguished Professor, Pediatrics, Infectious Diseases
  • Palmucci, Julia, Student, Molecular Genetics and Microbiology
  • Reed, Shelby Derene, Professor in Population Health Sciences, Duke Science & Society